These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9204349)

  • 1. Iopentol (Imagopaque) in vascular procedures. A multi-centre monitoring trial assessing adverse events and diagnostic information--results from 3,587 patients in Germany.
    Muth CP; Henseke P; Grynne BH
    Eur Radiol; 1997; 7 Suppl 4():S104-8. PubMed ID: 9204349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iopentol (Imagopaque 350) compared with diatrizoate (Urografin 370) in cerebral CT. A clinical trial assessing immediate and late (7 days) adverse events and diagnostic information (visualization quality and Hounsfield unit measurements).
    Valentine A; Jakobsen JA; Klaveness AJ
    Eur Radiol; 1997; 7 Suppl 4():S145-8. PubMed ID: 9204358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of iopentol (Imagopaque 350) in CT enhancement. A multi-centre monitoring trial assessing adverse events and diagnostic information--results from 1,823 patients in France.
    Oxaal M; Lambrechts M; Bunouf P; Menuet JF
    Eur Radiol; 1997; 7 Suppl 4():S109-14. PubMed ID: 9204350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iopentol (Imagopaque 300) compared with iohexol (Omnipaque 300) and diatrizoate (Urografin 292) in pediatric urography. A clinical trial assessing adverse events and diagnostic information.
    Lanning P; Brekke O
    Eur Radiol; 1997; 7 Suppl 4():S120-2. PubMed ID: 9204352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in abdominal CT. A multi-centre monitoring trial assessing adverse events and diagnostic information--results from 518 patients in Spain.
    Encina JL; Martí-Bonmatí L; Ronchera-Oms CL; Rodríguez V
    Eur Radiol; 1997; 7 Suppl 4():S115-9. PubMed ID: 9204351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iopentol (Imagopaque 250) compared with diatrizoate (Urografin 219) in endoscopic retrograde cholangio-pancreatography (ERCP). A clinical trial assessing safety (adverse events and S-pancreatic iso-amylase) and diagnostic information (VAS).
    Kruse A; Brock A; Rodenberg J; Nowakowska-Duawa E; Bjartveit K
    Eur Radiol; 1997; 7 Suppl 4():S131-4. PubMed ID: 9204355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iopentol (Imagopaque 350) compared with iohexol (Omnipaque 350) in pediatric cardioangiography. A clinical trial assessing adverse events, ECG, blood pressure and diagnostic information.
    Kunnen M; De Greef D; Skinningsrud K
    Eur Radiol; 1997; 7 Suppl 4():S123-6. PubMed ID: 9204353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iopentol (Imagopaque 300 and 350) compared with iohexol (Omnipaque 300 and 350) in cerebral and aortic arch angiography. A clinical trial assessing adverse events and diagnostic information.
    Ericsson K; Bjartveit K
    Eur Radiol; 1997; 7 Suppl 4():S152-5. PubMed ID: 9204360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in pediatric angiocardiography. A clinical trial assessing adverse events, ECG and diagnostic information.
    Piéchaud JF; Iserin L; Aggoun Y; Kachaner J; Skinningsrud K
    Eur Radiol; 1997; 7 Suppl 4():S127-30. PubMed ID: 9204354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of iopentol (Imagopaque 300 mg I/ml) compared with amidotrizoate (Peritrast 300 mg I/ml), both diluted to 2% (v/v), in imaging of the gastrointestinal tract in abdominal contrast enhanced CT. A clinical trial assessing patient tolerance, distribution of contrast medium and Hounsfield unit measurements.
    Friedrich JM; Skinningsrud K; Welter C; Eide H; Merkle E
    Eur Radiol; 1997; 7 Suppl 4():S140-4. PubMed ID: 9204357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iopentol (Imagopaque 300) compared with ioxaglate (Hexabrix 320) in knee arthrography. A clinical trial assessing immediate and late adverse events and diagnostic information.
    Railhac JJ; Brekke O
    Eur Radiol; 1997; 7 Suppl 4():S135-9. PubMed ID: 9204356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and electrocardiographic effects of iopentol in left ventricular angiography. Comparison of the low-osmolar, non-ionic iopentol (Imagopaque 350) and the hyper-osmolar, ionic metrizoate meglumine-Na-Ca (Isopaque Coronar 370) in patients with coronary heart disease.
    Vik-Mo H; Danielsen R; Skinningsrud K; Haider T; Bjørkhaug A
    Eur Radiol; 1997; 7 Suppl 4():S156-61. PubMed ID: 9204361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonionic contrast media in pediatric CT. A comparative study of intravenous use of iopentol and iohexol.
    Wiklund LM; Brolin I; Sjöholm K
    Acta Radiol; 1994 Mar; 35(2):186-90. PubMed ID: 8172749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind CT study comparing the safety and efficacy of iopentol and ioxaglate in paediatric patients.
    Sayegh N; Porée C; Baraton J; Skinningsrud K; Nantois C; Lallemand D
    Eur Radiol; 1996; 6(4):574-7. PubMed ID: 8798046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed CT of the kidneys after iopentol (Imagopaque 350) injection in patients with normal renal function. An assessment of the gradual decrease in opacification over 32 h after injection.
    Rickards D; Jakobsen JA; Klaveness AJ; Kjaersgaard P
    Eur Radiol; 1997; 7 Suppl 4():S149-51. PubMed ID: 9204359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative evaluation of 2 non-ionic contrast media, iopentol (350 mgI/ml) and iopamidol (370 mgI/ml) in coronary angiography].
    Maddestra N; Di Cesare A; Salute L; Toppetti A; Minguzzi P; Marelli C; Bonomo L
    Radiol Med; 1994 Oct; 88(4):396-400. PubMed ID: 7997610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary European intravenous clinical experience with a new, low osmolar, nonionic contrast medium: ioversol (Optiray).
    Le Mignon MM; Azau C; Arthaud A; Bonnemain B
    Eur J Radiol; 1991; 13(2):126-33. PubMed ID: 1743190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical profile of ioversol. A metaanalysis of 57 randomized, double-blind clinical trials.
    Floriani I; Ciceri M; Torri V; Tinazzi A; Jahn H; Noseda A
    Invest Radiol; 1996 Aug; 31(8):479-91. PubMed ID: 8854194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing surveillance of the safety profile of iodixanol in the outpatient CT setting: a prospective, multicenter, observational study of patient risk factors, adverse reactions and preventive measures in 9953 patients.
    Müller FH
    Rofo; 2014 Nov; 186(11):1028-34. PubMed ID: 24729407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial program for iopentol. A new nonionic ratio 3.0 contrast medium with emphasis on clinical phases I and II.
    Andrew E; Waaler A; Jakobsen J; Holager T; Lambrechts M; Moxnes A; Kruger Hagen E; Bach-Gansmo T
    Invest Radiol; 1988 Sep; 23 Suppl 1():S189-92. PubMed ID: 3058629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.